
Don't call me Chinese Frankenstein, says jailed scientist who tinkered with baby DNA
The Chinese scientist who was imprisoned for secretly creating the world's first genetically-engineered babies has claimed he will be remembered as China's Charles Darwin for ultimately eliminating natural selection.
He Jiankui, who shocked the scientific world in 2018 when he said he had rewritten the DNA of two twins, Lulu and Nana, told The Telegraph that he had no regrets over the controversial experiment. An investigation by Chinese authorities – which also revealed a third gene-edited baby – resulted in a three-year prison sentence.
'I hope people remember me as the 'Chinese Darwin' in 50 years,' said Mr He, who asked to be called a 'pioneer of gene editing'.
Mr He's defence of his work contrasts with his public image. He was dubbed 'China's Frankenstein' when it first emerged that he had illegally carried out gene editing on babies. He was sentenced to three years in jail in 2019.
While the case shocked the world at the time, but Mr He claimed he will be proved to have been on the right side of history. He predicted that countries, including the UK, would legalise gene editing in humans within the next two years – as he claims it would allow people to cure Alzheimer's and cancer.
The cost, he says, will be a few thousand dollars, suggesting that most parents will choose to edit embryos' DNA.
The scientist has returned to a laboratory in China after leaving prison in 2022, and has proposed resuming his research to eliminate Alzheimer's disease.
However, Mr He admitted that he was 'deeply worried' about where his work could ultimately lead.
Genetic editing – effectively cutting out parts of DNA and replacing it to alter genetic makeup – has been the subject of lab experiments for decades, as well as being a plentiful source of inspiration for science fiction. However, editing humans was seen as an ethical and scientific minefield, and was widely banned.
Mr He disregarded these concerns to conduct his own experiment on unborn babies. He ultimately announced on YouTube that 'two beautiful little Chinese girls, Lulu and Nana, came crying into the world as healthy as any other babies' after having their genetic code altered.
Mr He was a relative unknown in the cutting-edge field of gene editing. The son of rice farmers in China, he was a promising student and had won a scholarship to study in the US, including a fellowship at California's revered Stanford University before returning to China. However, he had not made an enormous impression on senior academics and so his announcement seemingly came from nowhere. He was just 34 when the scandal broke.
The twins' genes had been tweaked as IVF embryos using the Crispr gene editing technique to make them more resistant to HIV, which their father had contracted. 'I understand this work will be controversial,' Mr He said at the time, but added: 'I am willing to take the criticism.'
The backlash came swiftly. Shenzhen's Southern University of Science and Technology, where Mr He worked, distanced itself from the research. The experiment was slammed as deeply unethical, as well as medically unnecessary, and it was alleged that the twins' parents were not fully consulted about the potential risks.
In 2019, Mr He was arrested and sentenced to prison, with a court saying he had carried out 'illegal medical practices' while 'seeking fame and wealth'. It emerged that he had raised millions of investment for his own biotech start-ups.
Mr He declined to answer questions about his prison experience.
'Every pioneer or prophet must suffer'
However, he said he did not harbour any regrets over his work: 'If I go back to 2018, I will do it again, in exactly the same way.'
He said the response from the scientific community was unwarranted, but not unusual. 'I thought I had helped two families and their parents appreciated me. I did not expect that the world would respond so badly,' Mr He said.
'I once thought it is unfair. But now, I believe it is fair. Every pioneer or prophet must suffer.'
I will apologize for the gene edited baby experiment, only if their parents have requested it. However, they are happy with the results now.
— Jiankui He (@Jiankui_He) October 23, 2024
Mr He has compared himself to Edward Jenner, the English physician who discovered the smallpox vaccine and was initially mocked for his work. Satirists claimed patients would grow cow horns after being inoculated.
Last year, Mr He said he was attacked as he walked into his car, suffering multiple injuries, and that his assailant had been staking out his office for a week before the assault.
Despite the public backlash, the scientist said the gene-edited twins – as well as a third baby born to a different mother – are healthy and living normal lives.
Since his imprisonment, gene therapy, a less controversial treatment involving introducing new genes to fight disease, has made major breakthroughs. And gene editing has also advanced in the lab, including the recent creation of a 'woolly mouse' as a potential step to reviving the woolly mammoth.
However, seven years later, there is little sign of human gene editing experiments being repeated again.
China tightened up gene editing laws after Mr He's case, and the practice remains illegal in major countries as well as strongly discouraged by the World Health Organisation. Mr He has hit out at the scientific community that condemned him, saying Crispr's pioneers have wasted billions without helping patients.
After prison, he returned to the lab at the Wuchang University of Technology in Wuhan, the city that was cradle of the pandemic. Mr He ducked the question of whether Covid-19 might have escaped from a lab, saying he has no idea.
He is now working at a research park in Beijing 'with the help of an assistant and a few interns'.
A photographer is also frequently present, it appears. Mr He frequently posts on X, pronouncing one-sentence assertions such as 'Tinkering with human embryos will certainly be worth the risk' and 'Gene editing in human embryos will be as popular as iPhone' with portrait photos of himself in the lab.
Tinkering with human embryos will certainly be worth the risk. pic.twitter.com/ecsKZDnTFN
— Jiankui He (@Jiankui_He) February 24, 2025
Unnamed Chinese and American companies are funding his work, Mr He has said. No funding has come from the Chinese government, he said.
One person who has reportedly offered to finance his work is Ryan Shea, a US cryptocurrency entrepreneur, who praised him as a 'brave scientist ... willing to challenge conventional wisdom'. However, Mr He insisted that gene editing should benefit society 'rather than servicing a few rich men'.
Editing embryos' DNA will 'permanently eradicate cancer'
Mr He recently released a research proposal for a gene editing experiment aimed at fighting Alzheimer's – a disease that has no effective drug – with a mutation that may decrease the disease's impact.
His research proposal states that it will first be tested on mice, and then human embryos, but 'no human embryo will be implanted for pregnancy'.
He insisted his revolution is moving forward. In November, South Africa's national health department revised its ethics guidelines in a way that appeared to allow for genome editing, something that has also provoked an ethical outcry.
'The first gene edited baby after my work will be born in South Africa in two years,' Mr He said, predicting that the UK, Japan, Korea and Canada will follow.
There is little sign of British laws being changed to allow human gene editing, although a citizens' jury of people with genetic conditions overwhelmingly voted in favour of the idea in a project organised by the University of Cambridge in 2023.
In 20 years, gene editing in human embryos will be as popular as iPhone pic.twitter.com/BWoJ52h6ei
— Jiankui He (@Jiankui_He) December 21, 2024
Mr He argued that governments should pay 'in full' for the treatment, given how much it will ease the burden on health services. Editing embryos' DNA will not only eliminate Alzheimer's but 'permanently eradicate cancer', he claimed.
However, gene editing presents more than just economic and health concerns. There are ethical questions, too.
The rise of genetic editing techniques has raised the prospect of designer babies: embryos edited for eye-colour, athletic ability or intelligence. Mr He has said he opposed allowing billionaires to create superior children, and that we should ban gene editing for these purposes. But he does worry that his experiments have started to erase natural selection in a way that will be difficult to control.
Despite his hope to one day be remembered as the 'Chinese Darwin', Mr He admitted he is 'deeply worried that one day humans will no longer be controlled by Darwin's evolution'.
If that prediction comes true, Mr He will certainly be part of the story, for good or bad.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Herald Scotland
15 hours ago
- The Herald Scotland
Lord Sainsbury: Give Glasgow greater devolved powers
"A major challenge which government faces if it wants to increase Scotland's rate of growth is a way to find and support such clusters," he said. "All the evidence from other countries suggests that the only way to effectively support clusters is to do so at a city region level. Read more: "I appreciate in Scotland, unlike in England, metro mayors have not yet been introduced, but if you want to support high-tech clusters, this is something I think you should seriously consider, with Greater Glasgow being given powers similar to those devolved to Greater Manchester and the West Midlands." Lord Sainsbury was speaking at the Creating the Jobs of Tomorrow conference organised by Glasgow Chamber of Commerce, where he was introduced to the stage by former Labour chancellor and prime minister Gordon Brown. Mr Brown said growth and productivity have been perennial problems in the UK and Scotland, with innovation the key to boosting performance. A new study by economist Dan Turner, head of research at the Centre for Progressive Policy, has suggested this could unlock the creation of hundreds of thousands of high-value jobs. "There are huge sources of innovation and inventiveness in Scotland, just as has been traditional in our history," he said. "The question is can we turn that into scalable companies that stay in Scotland, invest in Scotland, create jobs in Scotland, and Dan's study suggests we could create 300,000 jobs in the next 10 years. "That's 300,000 well-paying jobs, 120,000 in the new industries, the spin-offs in terms of the service sector another 180,000 - that is a possibility if we invest in the infrastructure, the skills, and the development necessary to achieve that." Lord David Sainsbury (Image: Nate Cleary) Lord Sainsbury is a Labour peer and served as minister for science and innovation under Mr Brown and his prime ministerial predecessor, Tony Blair, between 1998 and 2006. He was appointed a life peer in 1997. Lord Sainsbury said there are new opportunities for employment and growth in sectors such as quantum computing, artificial intelligence and biotechnology. "There are economists that will argue that it is investment that is the engine of economic growth, but we have to realise today that capital flows easily around the world, and it flows as it has always done, to where the best investment opportunities are created by innovation," Lord Sainsbury said. "You can sit in London today and you can invest in Silicon Valley, you can invest in practically any country - until recently you could even invest in Chinese venture capital - because that is what modern communication enables you to do. That is why investment is not the real driver of the economy, it's innovation." Among the other speakers was Michael Spence, who won the Nobel Prize in Economics in 2001 for his work in the analysis of markets with information imbalances. Read more: "There are two things that [people] associate with Adam Smith correctly," Mr Spence said. "One the 'invisible hand', which is the market system is a reasonably efficient tool for decentralising and allocating resources. "That actually is not the most important thing that Adam Smith said, but it's the one that neo-conservatives remember because they elevate market systems to the status of a religion, rather than a way of accomplishing economic and social goals. The most important one for our purposes is specialisation. "Adam Smith meant specialisation within an economy, when of course everything that David Sainsbury talked about in the global economy is just the Adam Smith insight writ large, and of course it is the ultimate source of growth. "Without specialisation you don't get scale of spread your activity over too much territory, and you don't get innovation. You get nothing if everybody has to do everything. "The fundamental message I want to deliver today is that's still true, and that growth is fundamentally about specialisation and structural change."


Daily Mail
a day ago
- Daily Mail
Major HIV breakthrough forces hidden fragments of the virus to emerge so it can be cleared from the body
Experts could have found a way to be one step closer to curing HIV for good. Researchers in Australia has developed a new treatment that forces hidden fragments of the virus - normally concealed within human cells - to emerge and expose themselves to the immune system. The breakthrough could enable the body, aided by antiviral drugs, to detect and destroy any lingering viral reservoirs. HIV has remained incurable because the virus can integrate itself into a cell's DNA, laying dormant and undetectable to both medication and immune defenses. Scientists said they've created a nanoparticle capable of delivering genetic instructions to infected cells, prompting them to produce a signal that reveals the virus's presence. Dr Paula Cevaal of the Doherty Institute and co-author of the study told The Guardian that the feat was 'previously thought impossible'. Cevaal said: 'In the field of biomedicine, many things eventually don't make it into the clinic, that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality. 'But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus. 'So, from that point of view, we're very hopeful that we are also able to see this type of response in an animal, and that we could eventually do this in humans.' The discovery was first revealed in the journal Nature Communications, where researchers said they were initially so astonished that they had to rerun the tests. Further research would be needed to determine whether revealing the virus would be enough to trigger an immune response, with tests only being carried out in the lab. It could still take years before clinical trials for the drug began, when it would have to go through rigorous testing before reaching consumers. However, the advance represents another step forward for the 1.2 million Americans currently living with an HIV infection - for which they took drugs daily. An estimated 31,800 people were believed to be infected every year, although that's a 12 per cent decline on five years ago. Globally, nearly 40 million people have the virus. The new nanoparticle's based on mRNA technology, the same as was used in covid vaccines made by Pfizer and other vaccine manufacturers. In their paper, the scientists revealed that they could deliver mRNA instructions to cells using the nanoparticle. The mRNA then instruct cells to generate substances that reveal the presence of HIV, but only if the virus was present. The study done in the laboratory was carried out in cells donated by HIV patients.


North Wales Chronicle
a day ago
- North Wales Chronicle
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'